Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, shared a post on X about a paper by Stijn Franssen et al. published in the Journal of Clinical Oncology:
“Pretty cool data with the PUMP2 trial – HAIP for unresectable intrahepatic cholangiocarcinoma.
48 patients. 22 patients (44%) achieved a PR, and 42 patients (84%) disease control at 6 months. 5 patients (10%) converted to resection, of whom one had a pCR.
Median OS was 22.3 months (95% CI, 19.7 to 35.9 months). 1-year OS = 80.0% (95% CI, 69.6% to 91.9%), superior to the historical control of 47% (P < .001). 3-year OS = 31.5% (95% CI, 20.4% to 48.6%).
Definitely something I’ve been offering my patients if eligible.”
Title: Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma-PUMP-2 Trial
Authors: Stijn Franssen, Merve Rousian, Wills F. Filipe, Florian E. Buisman, Britte H.E.A. ten Haaft, Rutger-Jan Swijnenburg, Bianca Mostert, Nadia Haj Mohammad, Jeroen Hagendoorn, Michael Doukas, Heinz-Josef Klümpen, Marjolein Y.V. Homs, and Bas Groot Koerkamp
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Udhayvir Grewal.